Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)

Expanded access is currently available for this treatment.
Verified January 2017 by Biogen
Sponsor:
Information provided by (Responsible Party):
Biogen
ClinicalTrials.gov Identifier:
NCT02865109
First received: August 10, 2016
Last updated: January 17, 2017
Last verified: January 2017
  Purpose
To provide access to nusinersen to eligible patients with Infantile-onset Spinal Muscular Atrophy (SMA) (consistent with Type 1) to address a high-unmet medical need.

Condition Intervention
Infantile-onset Spinal Muscular Atrophy (SMA)
Drug: nusinersen

Study Type: Expanded Access     What is Expanded Access?
Official Title: Expanded Access Program (EAP) to Provide Nusinersen to Patients With Infantile-onset Spinal Muscular Atrophy (SMA)

Resource links provided by NLM:


Further study details as provided by Biogen:

Intervention Details:
    Drug: nusinersen
    Administered by intrathecal injection
    Other Names:
    • ISIS 396443
    • BIIB058
Detailed Description:
Availability of nusinersen at an existing clinical trial site will depend on territory eligibility. Program opening date will depend on regulatory requirements and center-specific factors. Participating sites will be added as they apply for the EAP. A doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria
  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Criteria

Key Inclusion Criteria:

  • Genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation, or compound heterozygote.
  • Onset of clinical signs and symptoms at ≤ 6 months (180 days) of age, consistent with infantile onset, Type I SMA
  • Patient whose care in the opinion of the treating physician meets, and is expected to continue to meet, the guidelines set out in the 2007 Consensus Statement for Standard of Care in SMA

Key Exclusion Criteria:

  • Patient is qualified to participate in an ongoing clinical trial with nusinersen
  • Participation in a prior nusinersen study
  • Previous exposure to nusinersen
  • History of brain or spinal cord disease that would interfere with the LP procedures or CSF circulation
  • Presence of implanted shunt for the drainage of CSF or implanted CNS catheter
  • Previous or current participation in a clinical trial with an investigational gene therapy for SMA
  • Participation in a study with an investigational therapy for SMA within 6 months or five half-lives of the investigational drug, whichever is the longer, prior to the first dose of nusinersen.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02865109

Contacts
Contact: Biogen medinfo@biogen.com

Locations
United States, Colorado
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
United States, Florida
Nemours Children's Hospital
Orlando, Florida, United States, 32827
United States, Illinois
Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611
United States, Massachusetts
Boston Children's Hospital
Boston, Massachusetts, United States, 02115
Australia, New South Wales
Sydney Children's Hospital
Randwick, New South Wales, Australia, 2031
Canada, Ontario
Children's Hospital at London Health Sciences Centre
London, Ontario, Canada, N6A 5A5
Canada, Quebec
Montreal Children's Hospital
Montreal, Quebec, Canada, H4A 3J1
Germany
Universitätsklinikum Freiburg
Breisgau, Freiburg, Germany, 79106
Universitätsklinikum Essen
Essen, Germany, 45147
Italy
Policlinico Agostino Gemelli
Rome, Latium, Italy, 00168
Ospedale Pediatrico Bambino Gesù
Vatican City, Rome, Lazio, Italy, 4 - 00165
Istituto Giannina Gaslini
Genova, Liguria, Italy, 16147
Sweden
The Queen Silvia Children's Hospital
Vitaminvägen, Gothenburg, Sweden, 2141685
United Kingdom
Royal Victoria Hospital
Belfast City, Belfast, United Kingdom, BT12 6BA
Sponsors and Collaborators
Biogen
Investigators
Study Director: Medical Director Biogen
  More Information

Responsible Party: Biogen
ClinicalTrials.gov Identifier: NCT02865109     History of Changes
Other Study ID Numbers: 232-SM-901 
Study First Received: August 10, 2016
Last Updated: January 17, 2017

Keywords provided by Biogen:
Spinal Muscular Atrophy
SMA
SMN
SMNRx
ISIS-SMNRx
ISIS-SMN Rx
ISIS 396443
ISIS-396443
ENDEAR
IONIS-SMNRx
IONIS-SMN Rx
EMBRACE
NURTURE
IONIS
BIOGEN
SHINE
Nusinersen

Additional relevant MeSH terms:
Atrophy
Muscular Atrophy, Spinal
Muscular Atrophy
Pathological Conditions, Anatomical
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Motor Neuron Disease
Neurodegenerative Diseases
Neuromuscular Diseases
Neuromuscular Manifestations
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on January 19, 2017